ABSTRACT
The most aggressive and invasive tumor cells often reside in hypoxic microenvironments and rely heavily on rapid anaerobic glycolysis for energy production. This switch from oxidative phosphorylation to glycolysis, along with up-regulation of the glucose transport system, significantly increases the release of lactic acid from cells into the tumor microenvironment. Excess lactate and proton excretion exacerbate extracellular acidification to which cancer cells, but not normal cells, adapt. We have hypothesized that carbonic anhydrases (CAs) play a role in stabilizing both intracellular and extracellular pH to favor cancer progression and metastasis. Here we show that proton efflux (acidification) using the glycolytic rate assay is dependent on both extracellular pH (pHe) and CA IX expression. Yet, isoform selective sulfonamide-based inhibitors of CA IX did not alter proton flux, which suggests that the catalytic activity of CA IX is not necessary for this regulation. Other investigators have suggested the CA IX cooperates with the MCT transport family to excrete protons. To test this possibility, we examined the expression patterns of selected ion transporters and show that members of this family are differentially expressed within the molecular subtypes of breast cancer. The most aggressive form of breast cancer, triple negative breast cancer (TNBC), appears to coordinately express the monocarboxylate transporter 4 (MCT4) and carbonic anhydrase IX (CA IX). This supports a possible mechanism that utilizes the intramolecular H+ shuttle system in CA IX to facilitate proton efflux through MCT4.
- Abbreviations
- TNBC
- Triple negative breast cancer
- CA
- Carbonic anhydrase
- HIF1
- Hypoxia Inducible factor 1
- CA IX
- Carbonic anhydrase isoform IX
- CA XII
- Carbonic anhydrase isoform XII
- CA II
- Carbonic anhydrase isoform II
- MCT1
- Monocarboxylate transporter 1
- MCT4
- Monocarboxylate transporter 4
- vATPase
- Vacuolar ATPase
- NHE1
- Na+/H+ exchanger
- GLUT1
- Glucose transporter 1
- NBCn1
- Na+/HCO3− co-transporter
- PDX
- Patient derived tumor graft
- USB
- Ureido substituted benzene sulfonamide